OCIER BLANCO: Open Payments
NPI 1912661364 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,200 in 116 payments from 14 companies in 2025. Trend: 2023 $1,015 · 2024 $1,659 · 2025 $2,200
Food & beverage: $2,200
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $345 |
| Otsuka America Pharmaceutical, Inc. | 13 | $271 |
| Neurocrine BioSciences, Inc. | 11 | $230 |
| Janssen Pharmaceuticals, Inc | 15 | $221 |
| Teva Pharmaceuticals USA, Inc. | 14 | $220 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $201 |
| Alkermes, Inc. | 11 | $189 |
| Vanda Pharmaceuticals Inc. | 11 | $136 |
| Lundbeck LLC | 5 | $129 |
| E.R. Squibb & Sons, L.L.C. | 5 | $114 |
Products named: CAPLYTA, REXULTI, INGREZZA, TRINTELLIX, INVEGA SUSTENNA, ARISTADA, AUSTEDO XR, COBENFY.
Industry payments across FL — which companies pay providers there.
